HomeNewsScience and Health NewsLATEST TEST RESULTS BOLSTER RENOVACARE STRATEGY TO SPRAY STEM CELLS ON WOUNDS AND BURNS FOR RAPID HEALING
LATEST TEST RESULTS BOLSTER RENOVACARE STRATEGY TO SPRAY STEM CELLS ON WOUNDS AND BURNS FOR RAPID HEALING
RenovaCare, Inc., (OTCQB: RCAR) today announced positive spray test results demonstrating that its novel SkinGun™ technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods.
These outcomes are especially promising to scientists developing patented RenovaCare CellMist™ and SkinGun™ technologies* for spraying fluids containing a patient’s own stem cells onto burns and wounds for rapid scar-free healing. «These results mark important technical milestones in our pathway to spraying patient wounds with their own stem cells to promote fast and natural skin repair," said Thomas Bold, President and CEO of RenovaCare, Inc. «Data from ongoing preclinical work supports our long-held conviction that our SkinGun™ technology is superior to standard methods for delivering fluids and stem cells to target sites, achieving excellent coverage while being extremely gentle to the cells.»
In addition to these tests showing high distribution and concentration patterns, the SkinGun™ recently demonstrated the ability to spray powerful yet delicate skin stem cells ultra-gently. Scientists reported impressive 97.3% cell viability after SkinGun™ spraying. Cell viability is essential to regenerating skin for burns, wounds, and cosmetic applications. Specifically, scientists at one of the world’s largest university hospitals, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité — Universitätsmedizin Berlin, sprayed human skin stem cells using the RenovaCare™ SkinGun™. Among technical aims of the study, was evaluation of several factors important to the regeneration of human skin, including cell yield, viability, metabolic activity, and cell growth. Positive results were reported from experiments related to each of these investigations, and cell growth was comparable to pipetting, the industry’s widely accepted ‘gold-standard’ for the deposition of cells.
(L.) RenovaCare SkinGun™ evenly sprays 200-times more droplets than conventional syringe (R.)
In these latest tests, scientists repeatedly sprayed fluids at various airflow rates using the RenovaCare SkinGunTM, resulting in 200-times more droplets than conventional ‘syringe deposition’. For example, in an 8cm diameter surface area the SkinGun™ delivered more than 20,000 evenly distributed droplets versus only 91 droplets by conventional needle and syringe methods. Scientists evaluated droplet size, distribution, and density alongside spray velocity and fluid viscosity in experiments conducted at Stem cell Systems GmbH (Berlin, Germany). Additional testing of the SkinGun™ remains ongoing. The RenovaCare medical-grade spray device gently sprays a well-dispersed mist of wound care and/or irrigation fluids using a patented liquid-into-air stream system. The device targets the estimated $45 billion plus wound care market in the U.S.
